Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes

We describe a new generation of protein-targeted contrast agents for multimodal imaging of the cell-surface receptors for vascular endothelial growth factor (VEGF). These receptors have a key role in angiogenesis and are important targets for drug development. Our probes are based on a single-chain recombinant VEGF expressed with a cysteine-containing tag that allows site-specific labeling with contrast agents for near-infrared fluorescence imaging, single-photon emission computed tomography or positron emission tomography. These probes retain VEGF activities in vitro and undergo selective and highly specific focal uptake into the vasculature of tumors and surrounding host tissue in vivo. The fluorescence contrast agent shows long-term persistence and co-localizes with endothelial cell markers, indicating that internalization is mediated by the receptors. We expect that multimodal imaging of VEGF receptors with these probes will be useful for clinical diagnosis and therapeutic monitoring, and will help to accelerate the development of new angiogenesis-directed drugs and treatments.

[1]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.

[2]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[3]  L. Ellis,et al.  Promises and pitfalls of anti-angiogenic therapy in clinical trials. , 2003, Trends in molecular medicine.

[4]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[5]  William R. Wagner,et al.  Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor , 2003, Circulation.

[6]  Stefanie Mandl,et al.  Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. , 1997, The American journal of pathology.

[8]  Vimalkumar A. Patel,et al.  In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  K. Claffey,et al.  Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. , 2006, Biomaterials.

[10]  K. Claffey,et al.  Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature , 2005, Molecular Cancer Therapeutics.

[11]  J. Tonn,et al.  Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. , 2002, The Journal of clinical investigation.

[12]  Wei Zhang,et al.  A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model , 2004, Angiogenesis.

[13]  H. Saji,et al.  Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. , 1999, Bioconjugate chemistry.

[14]  P. Angelberger,et al.  Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Huang,et al.  RESPONSE: re: initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models , 2000, Journal of the National Cancer Institute.

[16]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[17]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[18]  M. Dewhirst,et al.  Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.

[19]  T. Saga,et al.  Control of radioactivity pharmacokinetics of 99mTc-HYNIC-labeled polypeptides derivatized with ternary ligand complexes. , 2002, Bioconjugate chemistry.

[20]  M. Bryckaert,et al.  Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects , 1991, Journal of cellular physiology.

[21]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[22]  P. Valent,et al.  Characterization of 123I‐vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy , 2001, International journal of cancer.

[23]  James H Thrall,et al.  Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.

[24]  A. Guha,et al.  A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[26]  Gloria H Heppner,et al.  Nontransgenic models of breast cancer , 2000, Breast Cancer Research.

[27]  G. Vrensen,et al.  Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[29]  W. Schima,et al.  Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[30]  M. Backer,et al.  Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. , 2001, Bioconjugate chemistry.

[31]  M. Backer,et al.  Functionally active VEGF fusion proteins. , 2001, Protein expression and purification.

[32]  R. Haubner,et al.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.